Skip to main content
. 2020 Jul 28;25:e923278-1–e923278-17. doi: 10.12659/AOT.923278

Figure 6.

Figure 6

Clinical outcomes overall and by metabolizer phenotype. The analysis population consisted of patients who had a calculable day 30 C/D ratio based on central or local laboratory data. For all patients and within metabolizer subgroups, there were no statistically significant differences between treatments for any event. BKV, BK viremia; BKVN – BK virus nephropathy; BPAR – biopsy-proven acute rejection; CMV – cytomegalovirus; DGF – delayed graft function.